Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1NETWORK 1

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 1617Carcinoma, Renal Cell 497Urinary Bladder Neoplasms 459Carcinoma, Transitional Cell 233Breast Neoplasms 225Kidney Neoplasms 214Neoplasms 190Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 168Ovarian Neoplasms 161Melanoma 161Neoplasm Metastasis 142Lung Neoplasms 127Non-Muscle Invasive Bladder Neoplasms 104Pancreatic Neoplasms 101Stomach Neoplasms 99Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 82Carcinoma, Hepatocellular 76Sarcoma 75Esophageal Neoplasms 71Head and Neck Neoplasms 68Adenocarcinoma 67Triple Negative Breast Neoplasms 65Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Wilms Tumor 46Urologic Neoplasms 45

Interventions

enzalutamide 2Docetaxel 2Androgen Antagonists 2darolutamide 1apalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer × Genitourinary × 1 year × Clear all
NCT05901649 2026-06-05

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Bayer

Active not recruiting
700 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT00309985 2025-12-11

CHAARTED

Eastern Cooperative Oncology Group

Phase 3 Completed
790 enrolled 11 charts
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Bayer

Phase 3 Completed
1,306 enrolled 25 charts 2 FDA
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT07031258 2025-06-22

Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

Nanfang Hospital, Southern Medical University

Not yet recruiting
50 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡